AACR 2018 lung cancer advancements: how will the findings translate in clinic?


At the AACR Annual Meeting 2018 (April 14–18, IL, USA),back-to-back presentations highlighted the advances in immunotherapy treatments for lung cancer, the deadliest cancer worldwide with approximately 1.7 million deaths per year [1]. Researchers from across the globe presented their published anti-PD-1/anti-PD-L1 trials and the results will change the way some lung cancers are approached. The treatments: Pembrolizumab (Keytruda ®) plus chemotherapy fared significantly better than chemotherapy alone in nonsquamous Non-Small Cell Lung Cancer (NSCLC) in the Keynote-189 trial, as published in The New England Journal of Medicine  Nivolumab (Opdivo ®) plus ipilimumab (Yervoy ®) had significantly higher progression-free survival than...

To view this content, please register now for access

It's completely free